New drug combo aims to control rare blood cancers
NCT ID NCT05936359
First seen Nov 18, 2025 · Last updated May 16, 2026 · Updated 22 times
Summary
This early-stage study tests a new drug, INCA033989, given alone or with another drug (ruxolitinib) in 225 adults with myeloproliferative neoplasms, a group of blood cancers. The main goal is to check safety and find the best dose. Participants must have a specific gene mutation (CALR) and be expected to live more than 6 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOPROLIFERATIVE NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Aou Policlinico S. Orsola-Malpighi
RECRUITINGBologna, 40138, Italy
-
Azienda Ospedaliero-Universitaria Careggi (Aouc)
RECRUITINGFlorence, 50134, Italy
-
Chu Nimes
RECRUITINGNîmes, 30029, France
-
Fondazione Irccs Ca Granda Ospedale Maggiore
RECRUITINGMilan, 20122, Italy
-
Guys and St Thomas Nhs Foundation Trust
RECRUITINGLondon, SE1 9RT, United Kingdom
-
Hopital Maisonneuve-Rosemont, Montreal, Qc
RECRUITINGMontreal, Quebec, H1T 2M4, Canada
-
Hospital Saint Louis
RECRUITINGParis, 75010, France
-
Hospital Universitari I Politecnic La Fe
RECRUITINGValencia, 46026, Spain
-
Hospital Universitario 12 de Octubre
RECRUITINGMadrid, 28041, Spain
-
Institut Bergonie
RECRUITINGBordeaux, 33076, France
-
Institut Gustave Roussy
RECRUITINGVillejuif, 94805, France
-
Kagoshima University Hospital
RECRUITINGKagoshima, 890-8520, Japan
-
Mie University Hospital
RECRUITINGTsu, 514-0001, Japan
-
National Cancer Center Hospital East
RECRUITINGChiba-ken, 277-0882, Japan
-
Nippon Medical School Hospital
RECRUITINGTokyo, 113-8603, Japan
-
Odense University Hospital
WITHDRAWNOdense C, 05000, Denmark
-
Osaka Metropolitan University Hospital
RECRUITINGOsaka, 545-8586, Japan
-
Peter Maccallum Cancer Centre
RECRUITINGMelbourne, Victoria, 03000, Australia
-
Princess Margaret Cancer Center
RECRUITINGToronto, Ontario, M5G 2M9, Canada
-
Royal Adelaide Hospital
RECRUITINGAdelaide, South Australia, 05000, Australia
-
Royal Brisbane and Women'S Hospital
RECRUITINGHerston, Queensland, 04029, Australia
-
Sjaellands Universitetshospital
RECRUITINGRoskilde, 04000, Denmark
-
The Alfred Hospital
RECRUITINGMelbourne, Victoria, 03004, Australia
-
The Christie Nhs Foundation Trust Uk
RECRUITINGManchester, M20 4BV, United Kingdom
-
Universitatsklinikum Halle (Saale)
RECRUITINGHalle, 06120, Germany
-
University Medical Center Rwth Aachen
RECRUITINGAachen, 52074, Germany
-
University of Oxford
RECRUITINGOxford, OX3 7LE, United Kingdom
-
Universitätsklinikum Ulm
RECRUITINGUlm, 89081, Germany
-
Vejle Hospital
RECRUITINGVejle, 07100, Denmark
Conditions
Explore the condition pages connected to this study.